Isu Abxis Co Ltd
KOSDAQ:086890
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 980
7 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Isu Abxis Co Ltd
Cash from Financing Activities
Isu Abxis Co Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Isu Abxis Co Ltd
KOSDAQ:086890
|
Cash from Financing Activities
-₩16.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cash from Financing Activities
-₩273.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-18%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Cash from Financing Activities
-₩89.6B
|
CAGR 3-Years
-288%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Cash from Financing Activities
-₩181.7B
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cash from Financing Activities
-₩17.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash from Financing Activities
₩33.2B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
Isu Abxis Co Ltd
Glance View
ISU Abxis Co., Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 143 full-time employees. The company went IPO on 2009-02-03. The firm operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.
See Also
What is Isu Abxis Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
-16.5B
KRW
Based on the financial report for Jun 30, 2024, Isu Abxis Co Ltd's Cash from Financing Activities amounts to -16.5B KRW.
What is Isu Abxis Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
-1 922%
Over the last year, the Cash from Financing Activities growth was -1 922%.
You don't have any saved screeners yet
